San Diego’s Adamis Pharmaceuticals has submitted an application to the U.S. Food and Drug Administration seeking to begin human testing of a drug and product combo for treating opioid overdoses.

Adamis intends to develop a syringe platform that injects the existing drug naloxone, which blocks or reverses the effects of opioids, such as morphine, heroin and fentanyl.

This development follows the company’s epinephrine-filled syringe, called symjepi, which treats allergic reactions, including anaphylaxis. The FDA approved symjepi last June.

“Since FDA approval of our symjepi product, we have considered other drug candidates for use with our symject syringe injection platform,” said Dennis Carlo, Adamis CEO. “With the rapid increase in fentanyl related deaths and the persistence of widespread opioid addiction, we believe that there is a need for additional treatment options to help combat this crisis."

According to the Centers for Disease Control and Prevention (CDC), in 2016 drug overdoses resulted in approximately 64,000 deaths in the United States –more than 175 deaths per day.